We showed that cysteamine decreases the Mtb-specific response of T cells in a time- and dose-dependent manner; in particular, it decreases interferon (IFN)-γ, tumor necrosis factor (TNF), and interleukin (IL)-2-specific response, which are master drivers of inflammation in TB. This evidence concerns the gene IFNG and tuberculosis.